日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者的患者报告结局和定性访谈:来自III期EMBER-3试验的结果

Curigliano, G; O'Shaughnessy, J; Bidard, F-C; Casalnuovo, M L; Kim, S-B; Tokunaga, E; Aftimos, P; Saura, C; Carey, L A; Okera, M; Melo, E; Zagouri, F; Magallanes-Maciel, M; Karadurmus, N; Bahadur, S; Speck, R M; Wang, X A; Pradhan, K; Macey, J; Kitchen, H; Fairhurst, S; Miller, J; Jhaveri, K L; Harbeck, N

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results

帕拉塞群(Palazestrant)是一种新型口服完全雌激素受体拮抗剂(CERAN)和选择性雌激素受体降解剂(SERD),用于治疗ER+/HER2-晚期或转移性乳腺癌患者:1/2期研究结果

Hamilton, Erika P; Patel, Manish R; Borges, Virginia F; Meisel, Jane L; Okera, Meena; Alemany, Carlos A; Pluard, Timothy J; Wesolowski, Robert; Sabanathan, Dhanusha; Miller, Kathy D; Conlin, Alison K; McCarthy, Nicole; Shaw, Morena; Tonda, Margaret; Shilkrut, Mark; Lin, Nancy U

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

Capivasertib 和 fulvestrant 用于激素受体阳性晚期乳腺癌患者:来自 III 期 CAPItello-291 研究的常见不良事件的特征、时间进程和管理

Rugo, H S; Oliveira, M; Howell, S J; Dalenc, F; Cortes, J; Gomez, H L; Hu, X; Jhaveri, K L; Krivorotko, P; Loibl, S; Morales Murillo, S; Nowecki, Z; Okera, M; Park, Y H; Sohn, J; Toi, M; Iwata, H; Yousef, S; Zhukova, L; Logan, J; Twomey, K; Khatun, M; D'Cruz, C M; Turner, N C

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

Capivasertib治疗激素受体阳性晚期乳腺癌

Turner, Nicholas C; Oliveira, Mafalda; Howell, Sacha J; Dalenc, Florence; Cortes, Javier; Gomez Moreno, Henry L; Hu, Xichun; Jhaveri, Komal; Krivorotko, Petr; Loibl, Sibylle; Morales Murillo, Serafin; Okera, Meena; Park, Yeon Hee; Sohn, Joohyuk; Toi, Masakazu; Tokunaga, Eriko; Yousef, Samih; Zhukova, Lyudmila; de Bruin, Elza C; Grinsted, Lynda; Schiavon, Gaia; Foxley, Andrew; Rugo, Hope S

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial

对接受新辅助化疗的高危早期乳腺癌患者进行辅助阿贝西利联合内分泌治疗:monarchE随机临床试验的预设分析

Martin, Miguel; Hegg, Roberto; Kim, Sung-Bae; Schenker, Michael; Grecea, Daniela; Garcia-Saenz, Jose Angel; Papazisis, Konstantinos; Ouyang, QuChang; Lacko, Aleksandra; Oksuzoglu, Berna; Reeves, James; Okera, Meena; Testa, Laura; Shimizu, Chikako; Denduluri, Neelima; Adamchuk, Hryhoriy; Dakhil, Shaker; Wei, Ran; Forrester, Tammy; Fernandez, Maria Munoz; Zimmermann, Annamaria; Headley, Desiree; Johnston, Stephen R D

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer

一项开放标签、随机 II 期试验,旨在评估食物对晚期乳腺癌患者服用阿贝西利耐受性的影响

Lim, Elgene; Boyle, Frances; Okera, Meena; Loi, Sherene; Goksu, Sema Sezgin; van Hal, Gertjan; Chapman, Sonya C; Gable, Jonathon Colby; Chen, Yanyun; Price, Gregory L; Hossain, Anwar M; Gainford, M Corona; Ezquerra, Meritxell Bellet

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

阿贝西利联合内分泌治疗在激素受体阳性/人表皮生长因子受体2阴性的老年晚期乳腺癌患者中的安全性和有效性:MONARCH 2 和 3 试验的年龄特异性亚组分析

Goetz, Matthew P; Okera, Meena; Wildiers, Hans; Campone, Mario; Grischke, Eva-Maria; Manso, Luis; André, Valérie A M; Chouaki, Nadia; San Antonio, Belén; Toi, Masakazu; Sledge, George W Jr

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

阿贝西利联合氟维司群对激素受体阳性、ERBB2阴性且内分泌治疗后进展的乳腺癌患者总生存期的影响——MONARCH 2:一项随机临床试验

Sledge, George W Jr; Toi, Masakazu; Neven, Patrick; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A; Koh, Han; Grischke, Eva-Maria; Conte, PierFranco; Lu, Yi; Barriga, Susana; Hurt, Karla; Frenzel, Martin; Johnston, Stephen; Llombart-Cussac, Antonio

A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

西南伦敦癌症网络开展的一项关于化疗诱发发热性中性粒细胞减少症的前瞻性研究。根据NCAG/NCEPOD研究结果解读研究结果。

Okera, M; Chan, S; Dernede, U; Larkin, J; Popat, S; Gilbert, D; Jones, L; Osuji, N; Sykes, H; Oakley, C; Pickering, L; Lofts, F; Chowdhury, S

Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610

放射治疗肿瘤协作组 (RTOG) 8610 对前列腺癌患者核因子 κB 和趋化因子受体 CXCR4 共表达的评估

Okera, Meena; Bae, Kyoungwha; Bernstein, Eric; Cheng, Liang; Lawton, Colleen; Wolkov, Harvey; Pollack, Alan; Dicker, Adam; Sandler, Howard; Sweeney, Christopher J